DR. STEPHAN WADE MORRIS, M.D.
Osteopathic Medicine in Memphis, TN
License number
Tennessee MD0000019416
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
20 Dudley St C/O Memphis Bioworks Foundation - SUITE 900, Memphis, TN 38103
Phone
(901) 277-5582
(901) 866-1401 (Fax)
(901) 866-1401 (Fax)
Professional information
Antibodies For Recognition Of Alk Protein Tyrosine/Kinase Receptor
US Patent:
6696548, Feb 24, 2004
Filed:
Apr 9, 2001
Appl. No.:
09/827949
Inventors:
Stephan W. Morris - Memphis TN
A. Thomas Look - Boston MA
A. Thomas Look - Boston MA
Assignee:
St. Jude Childrens Research Hospital - Memphis TN
International Classification:
C07K 1600
US Classification:
5303879
Abstract:
The present invention is based on the identification and sequence determination of a novel gene, ALK, which is fused to the gene encoding nucleophosmin (NPM) in translocations present in t(2;5) lymphoma cells. Based on homologies to other proteins, the amino acid sequence of the polypeptide encoded by the ALK (Anaplastic Lymphoma Kinase) gene is a membrane-spanning protein tyrosine kinase (PTK)/receptor. Antibodies to the ALK PTK/receptor and methods utilizing such antibodies are described, as are methods of using the ALK gene to isolate ligands for the ALK PTK/receptor.
Dr. Stephan W Morris, Memphis TN - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
20 Dudley St STE 900, Memphis 38103
(901) 277-5582 (Phone), (901) 866-1401 (Fax)
(901) 277-5582 (Phone), (901) 866-1401 (Fax)
Languages:
English
Education:
Medical School
Louisiana State University Health Shreveport / School of Medicine
Graduated: 1980
Louisiana State University Health Shreveport / School of Medicine
Graduated: 1980
Dr. Stephan W Morris, Memphis TN - MD (Doctor of Medicine)
Specialties:
Hematology, Hematology & Oncology
Address:
20 Dudley St, Memphis 38103
(901) 866-1401 (Fax)
(901) 866-1401 (Fax)
Languages:
English
Kits For Detecting Chromosomal Rearrangements
US Patent:
6451997, Sep 17, 2002
Filed:
Sep 28, 2000
Appl. No.:
09/670827
Inventors:
Stephan W. Morris - Memphis TN
A. Thomas Look - Memphis TN
A. Thomas Look - Memphis TN
Assignee:
St. Jude Childrens Research Hospital - Memphis TN
International Classification:
C07H 2104
US Classification:
536 2431, 536 231, 536 232, 536 234, 536 235, 435810
Abstract:
The present invention is based on the identification and sequence determination of a novel gene, ALK, which is fused to the gene encoding nucleophosmin (NPM) in translocations present in t(2;5) lymphoma cells. Based on homologies to other proteins, the amino acid sequence of the polypeptide encoded by the ALK (Anaplastic Lymphoma Kinase) gene is a membrane-spanning protein tyrosine kinase (PTK)/receptor. Antibodies to the ALK PTK/receptor and methods utilizing such antibodies are described, as are methods of using the ALK gene to isolate ligands for the ALK PTK/receptor.
Stephan Wade Morris, Memphis TN
Specialties:
Internist
Address:
20 Dudley St, Memphis, TN 38103
Fusion Genes Associated With Acute Megakaryoblastoc Leukemias
US Patent:
7329744, Feb 12, 2008
Filed:
Apr 23, 2002
Appl. No.:
10/475917
Inventors:
Stephan W. Morris - Memphis TN, US
Zhigui Ma - Memphis TN, US
Johann K. Hitzler - Toronto, CA
Zhigui Ma - Memphis TN, US
Johann K. Hitzler - Toronto, CA
Assignee:
St. Jude Children's Research Hospital Inc. - Memphis TN
The Hospital for Sick Children
The Hospital for Sick Children
International Classification:
C07H 21/04
US Classification:
536 234, 536 231, 536 2431, 530350
Abstract:
The invention relates to human nucleotide sequences which occur as a result of the t(1;22)(p13;q13) chromosomal translocation event which is known to occur almost invariable in young children with acute megakaryoblastic leukemia. The translocation results in the formation of fusion genes which encode fusion proteins. The invention provides the nucleotide sequences of transcripts of the fusion genes and the amino acid sequences of the fusion proteins encoded thereby. Also provided are methods for detecting the t(1, 22) translocation, for identifying agents capable of binding to the fusion protein and for identifying agents useful for treating patients with acute megakaryoblastic leukemia.
Methods And Compositions For The Diagnosis And Treatment Of Cancer Resistant To Anaplastic Lymphoma Kinase (Alk) Kinase Inhibitors
US Patent:
8383793, Feb 26, 2013
Filed:
Apr 15, 2010
Appl. No.:
12/761050
Inventors:
Stephan W. Morris - Germantown TN, US
Qin Jiang - Memphis TN, US
Xiaoli Cui - Memphis TN, US
Liquan Xue - Cordova TN, US
Qin Jiang - Memphis TN, US
Xiaoli Cui - Memphis TN, US
Liquan Xue - Cordova TN, US
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C07H 21/04, C12N 15/00
US Classification:
536 231, 435 691
Abstract:
Compositions and methods for the diagnosis and treatment of a cancer that is resistant to at least one anaplastic lymphoma kinase (ALK) kinase inhibitor are provided herein. The present invention is based on the discovery of mutations within ALK that confer resistance to at least one ALK kinase inhibitor. Polynucleotides and polypeptides having at least one ALK inhibitor resistance mutation are provided and find use in methods and compositions useful in the diagnosis, prognosis, and/or treatment of diseases associated with aberrant ALK activity, more particularly, those that are resistant to at least one ALK kinase inhibitors. Methods and compositions are also provided for the identification of agents that can inhibit the kinase activity and/or reduce the expression level of the ALK resistance mutants.
Human Alk Protein Tyrosine Kinase
US Patent:
5770421, Jun 23, 1998
Filed:
Oct 12, 1995
Appl. No.:
8/542363
Inventors:
Stephan W. Morris - Memphis TN
A. Thomas Look - Memphis TN
A. Thomas Look - Memphis TN
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C12N 912, A61K 3816
US Classification:
435194
Abstract:
The present invention is based on the identification and sequence determination of a novel gene, ALK, which is fused to the gene encoding nucleophosmin (NPM) in translocations present in t(2;5) lymphoma cells. Based on homologies to other proteins, the amino acid sequence of the polypeptide encoded by the ALK (Anaplastic Lymphoma Kinase) gene is a membrane-spanning protein tyrosine kinase (PTK)/receptor. Antibodies to the ALK PTK/receptor and methods utilizing such antibodies are described, as are methods of using the ALK gene to isolate ligands for the ALK PTK/receptor.
Nucleic Acid Sequences And Fusion Proteins Present In Human T(2;5) Lymphoma
US Patent:
5529925, Jun 25, 1996
Filed:
Dec 3, 1993
Appl. No.:
8/160861
Inventors:
Stephan W. Morris - Memphis TN
A. Thomas Look - Memphis TN
A. Thomas Look - Memphis TN
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C12N 1554, C12N 912
US Classification:
4352523
Abstract:
The present invention is based on the identification and sequence determination of fusion proteins generated by translocation which is present in t(2:5) lymphoma cells. Using either the amino acid or nucleic acid sequences of the fusion proteins disclosed herein, the present invention provides methods of detecting and treating t(2;5) lymphoma.
Method Of Detecting A Chromosomal Rearrangement Involving A Breakpoint In The Alk Or Npm Gene
US Patent:
6174674, Jan 16, 2001
Filed:
Jun 19, 1998
Appl. No.:
9/100089
Inventors:
Stephan W. Morris - Memphis TN
A. Thomas Look - Memphis TN
A. Thomas Look - Memphis TN
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C12Q 168, C07H 2102, C07H 2104
US Classification:
435 6
Abstract:
The present invention is based on the identification and sequence determination of a novel gene, ALK, which is fused to the gene encoding nucleophosmin (NPM) in translocations present in t(2;5) lymphoma cells. Based on homologies to other proteins, the amino acid sequence of the polypeptide encoded by the ALK (Anaplastic Lymphoma Kinase) gene is a membrane-spanning protein tyrosine kinase (PTK)/receptor. Antibodies to the ALK PTK/receptor and methods utilizing such antibodies are described, as are methods of using the ALK gene to isolate ligands for the ALK PTK/receptor.